Ivermectin and Gynecologic Cancer: What are the data?

•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to ef...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology reports Jg. 60; S. 101803
Hauptverfasser: Mujumdar, Vaidehi, Huang, Marilyn, Smith, Lindsey Chippendale, Musa, Fernanda
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Elsevier Inc 01.08.2025
Elsevier
Schlagworte:
Anti-helminthic
COVID-19
Gynecologic cancers
Ivermectin
Wonder drug
COVID-19
Gynecologic cancers
Wonder drug
Anti-helminthic
Ivermectin
ISSN:2352-5789, 2352-5789
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2025.101803